

DAFTAR PUSTAKA

- Abraham, N. M., Lamlerthton, S., Fowler, V.G., Jefferson, K.K. 2012. Chelating agents exert distinct effects on biofilm formation in *Staphylococcus aureus* depending on strain background: role for clumping factor B. *J Med Microbiol* 61:1062-1070.
- Ahmad, A., Khan, A., Kumar.P., Bhatt, R.P & Manzoor,N. 2011. Antifungal activity of *Coriaria Nepalensis* essential oil by disrupting ergosterol biosynthesis and membrane integrity against *Candida*. *Yeast.*, 28: 611-617.
- Ali I. Khan F. G., Suri K. A., Gupta B. D., Satti N. K., Duttt P., Afirin F., *et al.*, 2010. *In vitro* antifungal activity of hydroxychavicol isolated from *Piper betle*. *L . Ann Clin. Microbiol Antimicrobial*, 9(7): 1- 9.
- Alangaden, G.J. 2011. Nosocomial fungal infections: epidemiology, infection control, and prevention. *Infect. Dis. Clin. N. Am.*, 25: 201–225. DOI:10.1016/j.idc.2010.11.003.
- Anonim. 2000. Antibacterial and antifungal drug discovery: companies are racing to keep pace with the emergence of drug-resistant microorganisms. *Nature Biotechnol.*, 18(suppl):IT24-IT26.
- Arendrup, M.C. 2010. Epidemiology of invasive candidiasis. *Curr Opin Critical Care*, 16:445-452.
- Ashley, E.S.D., Lewis, R., Lewis, J., Martin, C., Andes, D. 2006. Pharmacology of systemic antifungal agents. *Clin. Infect. Dis.*, 43(Suppl 1): S28-S39.
- Awang, N., Baba, I., Yamin, B.M., Halim, A.A., 2011. Preparation, characterization and antimicrobial assay of 1,10-phenanthroline and 2,2'-bipyridyl adducts of cadmium(II) *N*-sec-butyl-*N*-propyldithiocarbamate: crystal structure of Cd[S2CN(*i*-C4H9)(C3H7)]2(2,2'-bipyridyl). *World Appl. Sci. J.*, 12(9):1568-1574.
- Banin, E., Brady, K.M., Greenberg, E.P. 2006. Chelator-induced dispersal and killing of *Pseudomonas aeruginosa* cells in a biofilm. *Appl Environ Microbiol*, 2064-2069.
- Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E.M., Luzzati, R., *et al.* 2013. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. *J.Clin.Microbiol.*, 51(12):4167-4172.
- Berman, J., Sudbery, P.E., 2002. *Candida albicans*: a molecular revolution built on lessons from budding yeast. *Natur. Rev. Microbiol.*, 3:9118 – 9130.
- Boumans, H., Van Gaalen, M.C.M., Grivell, L.A and Berden, A., 1997. Membranes and Bioenergetic: Differential Inhibition of the Yeast bc₁ Complex by Phenanthrolines and Ferroun: Implication for Structure and Catalytic Chem. *J.Biol. Chem.* 272 : 16753-60

- Brown, G.D., Denning, D.W., Gow, N.A.R., Levitz, S.M., Netea, M.G., White, T.C. 2012. Hidden killers: human fungal infections. *Sci Trans Med*, 4(165):165rv13.
- Butts, A. & Krysan, D.J. 2012. Antifungal drug discovery: something old and something new. *PLoS Pathog.*, 8(9): e1002870. doi:10.1371/journal.ppat.1002870
- Caamal-Fuentes, E., Torres-Tapia, L.W., Simá-Polanco, P., Peraza-Sánchez, S.R., Moo-Puc, R. 2011. Screening of plants used in Mayan traditional medicine to treat cancer-like symptoms. *J Ethnopharmacol*, 135: 719–724.
- Calderone, R. A. 2002. Introduction and historical perspectives. In R. A. Calderone (ed.), *Candida and candidiasis*. ASM Press, Washington, DC., 3-13.
- Calderone, R.A. & Fonzi, W.A. 2001. Virulence factors of *Candida albicans*. *Trends Microbiol*, 9:327-335.
- Canton, E., Peman, J., Viudes A., Quindos G., Gobernado M., 2003. Espinel-Ingroff A: Minimum fungicidal concentrations of amphotericin B for bloodstream *Candida* species. *Diagnos. Microbiol. Infect. Dis.*, 45:203-206.
- CCRC, 2014. Cancer Chemoprevention Research Center. Revisi Dokumen 1-7. Fakultas Farmasi UGM.
- Chapman, S.W., Dismukes, W.E., Proia, L.A., Bradsher, R.W., Pappas, P.G., *et al.* 2008. Clinical practice guidelines for the management of patients with blastomycosis: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 46:1801–1812.
- Chander, J., Singla, N., Sidhu, S.K., Gombar, S. 2013. Epidemiology of *Candida* blood stream infections: experience of a tertiary care centre in North India. *J Infect. Dev. Ctries.*, 7(9):670-675. DOI: 10.3855/jidc.2623.
- Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T. and Ghannoum, M.A., 2001. Biofilm formation by the fungal pathogen *Candida albicans* : development, architecture, and drug resistance. *J. Bacteriol.*, 183; 5385–5394.
- Chandroleka, S., Ramya, K., Chandramohan, G., Dhanasekaran, D., Priyadharshini, A., Panneerselvam, A. 2014. Antimicrobial mechanism of copper (II) 1,10-phenanthroline and 2,20-bipyridyl complex on bacterial and fungal pathogens. *J. Saudi Chem. Soc.*, (In press) DOI:10.1016/j.jscs.2011.11.020
- Chiu, Y.S., Chang, S.C., Hsueh, P.R., Wang, J.L., Sun, H.Y., Chen, Y.C. 2006. Survey of amphotericin B susceptibility of *Candida* clinical isolates determined by Etest. *J Microbiol Immunol Infect*, 39:335-341.

- CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth Informational Supplement. CLSI document M27-S4. Wayne, PA: Clinical and Laboratory Standards Institute.
- Colombo, A.L. & Guimaraes, T. 2003. Epidemiology of heterogenous infections due to *Candida* spp. *Rev Soc Bras Med Trop* 36:599-607.
- Coyle B., Kinella P., McCann M., Devereu M., O'Connor R., Clynes M and *et al.*, 2004. Induction of apoptosis in yeast and mammalian cells by exposure to 1,10-phenantroline metal complexes. *Toxicol In Vitro* 18(1):63-70.
- Collin,V.G. 1957. Planktonic Bacteria. *J Gen Microbiol*64 : 268-272.
- Czaika VA & Lam PA. 2013. Trichophyton mentagrophytes cause underestimated contagious zoophilic fungal infection. *Mycoses*, 56(Suppl 1): 33-37.
- Dabas, P.S. 2013.An approach to etiology, diagnosis and management of different types of candidiasis. *J Yeast Fungal Res*, 4(6):63-74.
- Da Silva Barros, M.E., de Assis Santos, D., Hamdan J.S. 2007. Evaluation of susceptibility of *Trichophyton mentagrophytes* and *Trichophyton rubrum* clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). *J. Med. Microbiol.*, 55:809-818.
- Davey, M.E.&O'toole,G.A. 2000. Microbialbiofilms: fromecologyto molecular genetics. *Microbiol Mol Biol Rev* 64(4):847–867.
- Dholariya, H.R., Patel, K.S., Patel, J.C., Patel, K.D. 2013. Dicoumarol complexes of Cu(II) based on 1,10-phenanthroline: synthesis, X-ray diffraction studies, thermal behavior and biological evaluation. *Spectrochim. Acta. A Mol. Biomol. Spectrosc.*, 108:319-328. DOI: 10.1016/j.saa.2012.09.096.
- Diekema, D., Arbefeville, S., Boyken, L., Kroeger, J., Pfaller, M. 2012. The changing epidemiology of healthcare-associated candidemia over three decades. *Diagn.Microbiol. Infect. Dis.*, 73(1):45-48. DOI: 10.1016/j.diagmicrobio.2012.02.001.
- Dignani, M.C. & Anaissie, E. 2004. Human fusariosis, *Clin Microbiol Infect*, 10 (Suppl. 1), 67–75.
- Donlan, R.M. 2002. Biofilm: microbial life on surface. *Emerg. Infect. Dis.*, 8(9):881-890.
- Dumitru, R., Hornby, J. M. and Nickerson, K. W.2004. Defined anaerobic growth medium for studying *Candida albicans* basic biology and resistance to eight antifungal drugs. *Antimicrob. Agents Chemother.*,48:2350-2354.
- Eggimann, P., Garbino, J. & Pittet, D. 2003. Epidemiology of *Candida* species infections in critically ill non immunosuppressed patients. *Lancet Infect. Dis.*, 3: 685–702.
- Eloff, J.N. 2004. Quantification the bioactivity of plant extracts during screening and bioassay guided fractionation. *Phytomedicine*, 11: 370–371.

- Enoch, D.A., Ludlam, H.A., Brown, N.M. 2006. Invasive fungal infections: a review of epidemiology and management options. *J. Med. Microbiol.*, 55:809-818.
- Galgiani, J.N., Ampel, N.M., Blair, J.E., Cantanzaro, A., Johnson, R.H., Stevens, D.A. *et al.* Coccidioidomycosis. *Clin Infect Dis*, 41:1217–1223.
- Garrett, T.R., Bhakoo, M., Zhang, Z. 2008. Bacterial adhesion and biofilm son surfaces. *Prog Nat Sci* 18(9):1049–1056
- Geurts, N., Opdenakker, G., van den Steen, P.E. 2012. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. *Pharmacol. Ther.*, 133: 257–279.
- Ghannoum, M.A. & Rice, L.B. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clin. Microbiol. Rev.*, 12(4):501-517.
- Gomleksiz, M., Alkan, C., Erdem, B. 2013. Synthesis, characterization and antibacterial activity of 2-p-tolyl-1H-imidazo[4,5-f][1,10] phenanthroline and its Co(II), Ni(II) and Cu(II) complexes. *Bull. Chem. Soc. Ethiop.* 27(2):213-220. DOI: <http://dx.doi.org/10.4314/bcse.v27i2.6>
- Grubb, S.E.W., Murdoch, C., Sudbery, P.E., Saville, S.P., Ribot, J.L.L., and Thornhill, M.H., 2008. Candida albicans – endothelial cells interaction: a key step in the pathogenesis of systemic Candidiasis. *Infect and Immunity.*, 76 (10): 4370-4377.
- Hall-Stoodley, L., Costerton, J.W., Stoodley, P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2(2):95–108
- Handanu, R., Anwar, C., Jumina, Mustofa. 2005. Synthesis of antimalarial 3-(2-hydroxyethyl)-2-methyl-1,10-phenanthroline-4-ol from 8-aminoquinoline. *Sains dan Sibernatika*, 18(3): 297-307.
- Hasrulliana, N.W., Suyoso, S., Rosita, C. 2010. Manifestasi klinis dan identifikasi spesies penyebab Kandidiasis oral pada pasien HIV/AIDS RSUD Dr. Soetomo. *Berkala I. Kes. Kul. Kel.*, 22:11-16.
- Havlickova, B., Gzaika, V.A., Friedrich, M. 2008. Epidemiological trends in skin mycoses worldwide. *Mycoses* 51(sup. 4):2-15.
- Hetrick, E.M., Shin J.H., Paul H.S., and Schoenfisch M.H., 2009. Anti-biofilm efficacy of nitric oxide-releasing silica nano particles. *Biomaterials* 30(14): 2782–89.
- Hii, I. M., Chang, H.L., Lin, L.C., Lee, Y.L., Liu, Y.M., Liu, C.E., *et al.*, 2013. Changing epidemiology of candidemia in a medical center in middle Taiwan. *J. Microbiol. Immunol. Infect.* PII: S1684-1182(13)00162-X. DOI: 10.1016/j.jmii.2013.08.017.

- Hurlow, J., Couch, K., Laforet, K., Bolton, L., Metcalf, D., Bowler, P. 2015. Clinical biofilms: a challenging frontier in wound care. *Adv Wound Care* 4(5):295–301
- Inamadar, A.C. & Palit, A. 2003. The genus *Malassezia* and human disease. *Indian J Dermatol Venereol Leprol* 69 (4): 265–270
- Isham, N & Ghannoum, M.A. 2006. Determination of MICs of Aminocandin for *Candida* spp. and Filamentous Fungi. *J. Clin. Microbiol.*, 44(12):4342–4344.
- Jabra-Rizk, M., Falker, W.A., Meiller, T.F. 2004. Fungal biofilms and drug resistance. *Emerg. Infect. Dis.*, 10(1): 14–19.
- Juda, M., Paprota, K., Jaloza, D., Malm, A., Rybojad, P. & Goździuk, K. 2008. EDTA as a potential agent preventing formation of *Staphylococcus epidermidis* biofilm on polychloride vinyl biomaterials. *Ann Agric Environ Med* 15:237–241.
- Jung, J.Y., Jo, G.H., Kim, H.S., Park, M.Y., Shin, J.H., Chin, B.S., Bang, J.H. & Shin, H.Y. 2012. Disseminated penicilliosis in a Korea human immune deficiency virus infection patient from Laos. *J. Korean. Med. Sci.*, 27(6): 697–700.
- Kauffman, C.A., Bustamante, B., Chapman, S.W., Pappas, P.G. 2007. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 45:1255–1265.
- Khan, M.S.A., Ahmad I., Aqil F., Owais M., Shahid M., and Musarrat J., 2010. Virulence and pathogenicity of fungal pathogens with special reference to *Candida albicans*. *Combat. Fungal Infec.*, 2: 21–45.
- Kojic, E.M. & Darouiche R.O. 2004. *Candida* infections of medical devices. *Clin Microbiol.*, 17:255–267.
- Kokare, C.R., Chakraborty, S., Khopade, A.N., Mahadik, K.R. 2009. Biofilm: Importance and applications. *Indians journal of Biotechnology* .Vol. 8.
- Kuete, V. 2010. Potential of Cameroonian plants and derived products against microbial infections: a review. *Planta Med*, 76:1479–1491.
- Kullerberg, B.J. & Arendrup, M.C. 2015. Invasive candidiasis. *N Engl J Med*, 373(15):1445–1456.
- Kumamoto, C.A., 2002. *Candida* biofilm. *Curr Opin Microbiol*, 5(6): 608–611.
- Kuhn, D. M. & Ghannoum, M. A. 2004. *Candida* biofilms: antifungal resistance and emerging therapeutic options. *Curr Opin Investig Drugs* 5: 186–197.
- Lakshmipathy, D.T. & Kannabiran, K. 2010. Review on dermatomycosis: pathogenesis and treatment. *Nat Sci*, 2(7): 726–731.
- Larabi, M., Legrand P., Appel M., Gil S., Lepoivre M., Devissaguet J.P., Piusieux F., et al., 2001. Reduction of NO synthase expression and tumor necrosis

factor alpha production in macrophages by Amphotericin B. *Lipid Carriers*, 45(2):553-562

- Lertvannait, O. & Suankratay, C. 2013. Systemic trichosporonosis: a mini-review. *J Infect Dis Antimicrob Agents*, 30:57-61.
- Lewis, R.E. 2007. Antifungal Pharmacology. Doctor fungus.Update 1/27/20079: 23:00 AM. Available from URLhttp://www.doctorfungus.org/thedrugs/antif_pharm.php
- Loeffler, J. & Stevens, D.A. 2003. Antifungal drug resistance. *Clin. Infect. Dis.*, 36(Suppl 1):S31-S41.
- Luman, C.R & Catellano, F.N.2003. Phenantroline ligands in comprehensive coordination chemistry II. Elsevier. ISBN 978-0-08-043748-4
- Ma, C.F., Li, F.Q., Shi, L.N., Hu, Y.A., Wang, Y., Huang, M., *et al.* 2013. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China.*BMC Infect. Dis.*, 13:337. DOI: 10.1186/1471-2334-13-337.
- Mamahit, E.R.S., Rahardjo, E., Lutam, B., Oktarina, C., Sihombing, S., Harun, S. 2000. Validasi pemeriksaan infeksi seksula secara pendekatan sindrom pada kelompok wanita berperilaku risiko tinggi.*Bul. Penelit.Kesehat.*, 28(2&3):460-472.
- Maric, S. & Vranes, J. 2007. Characteristics and significance of microbial biofilm formation. *Period Bilogor* 109:115–121
- Maschmeyer, G., Haas, A., Cornely, O.A. 2007. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. *Drugs.*, 67(11): 1567-601.
- Mayer, F.L., Wilson D., and Hube B., 2013. *Candida albicans* pathogenicity mechanisms. *Virulence*, 4(2):119-128.
- Mc Cann, M, Geraghty, M., Derevereux, M., O'Shea, D., Mason, J., O'Sullivan, L. 2000. Insight into the mode of action of the anticandida activity of 1,10-phenantroline and its metal chelates. *Metal Based Drugs* 7(4):185—193.
- Mc Cann, M., Kellett, A., Kavanagh, K., Derevereux, M., Santos, A.L.S. 2012.Deciphering the antimicrobial activity of phenanthroline chelators. *Curr Med Chem* 19(1):1-12
- Miyoshi, S. & Shinoda, S. 2000. Microbial metalloproteases and pathogenesis. *Micobes. Infect.*, 2(1):91-98.
- Menzin, j., Mayer, J.L Friedman, M., Perfect, J.R., Langston, A.A., Danna, R.P & Papadopoulos, G. 2009. Mortality, Length of hospitalization and costs associated with invasive fungal infections in higrisk patients. *Am. J. Health. Syst. Pharm.*, 66: 1711-1717.
- Monroe, D. 2007. Looking for chinks in the armor of bacterial biofilms. *PLoS Biol* 5(11): e307.doi:10.1371/journal.pbio.0050307.

- Moon, J. H., Kim, C., Lee, H.S., Kim, S.W., Lee, J.Y. 2013. Antibacterial and antibiofilm effects of iron chelators against *Prevotellaintermedia*. *J Med Microbiol*, 62:1307-1316.
- Mustofa. 2006. *In vitro* antiplasmodial activity and stage-specificity of 1,10-phenanthroline derivatives on *Plasmodium falciparum* cycles. *BIK.*,38(4).1-7.
- Mustofa, Jumina, Nuryastuti, T., Sholikhah, E.N., 2014. Potensi antijamur senyawa turunan (1)-N-Benzoil-1,10-fenantrolin untuk melawan resistensi infeksi jamur. *Paten*, No. Pendaftaran : P00201402808
- Mustofa, Yapi, A.D., Valentin, A., Tahir, I. 2003. *In vitro* antiplasmodial activity of 1,10-phenanthroline derivatives and its quantitaive structure-activity relationship. *BIK.*, 35(2): 67-74.
- Myers, R.S.2006. Immunizing and antimicrobial agents. *MEDH.*, 401: 1-6.
- Mamahit, E.R.S., Rahardjo, E., Lutam, B., Oktarina, C., Sihombing, S., Harun, S. 2000. Validasi pemeriksaan infeksi seksula secara pendekatan sindrom pada kelompok wanita berperilaku risiko tinggi. *Bul. Penelit. Kesehat.*, 28(2&3):460-472.
- Nazik, H., Penner, J.C., Ferreira, J.A., Haagensen, J.A.J., Cohen, K., Spormann, A.M. 2015. Effect of iron chelators on the formation and development of *Aspergillus fumigatus* biofilm. *Antimicrob Agents Chemother*, 59:6514–6520.doi:10.1128/AAC.01684-15
- Ndosiri, N.B., Agwara, M.O., Ndifon, P.T., Mohamadou, A., Boom, F.F. 2015. Synthesis, characterization, crystal structure and antimicrobial activities of a dimeric copper (1) chloride-phenanthroline complex $\{[Cu(C_{12}H_8N_2)_2Cl].5.5H_2O\}_2n$. *Int J Res Chem Pharm Sci* 2(6):63-69.
- Ndosiri, N.B., Agwara, M.O., Paboudam, A.G., Ndifon, P.T., Yufanyi, D.M. *et al.*, 2013. Synthesis, characterizationand antifungalactivitiesof Mn(II), Co(II), Cu(II), and Zn(II) mixed-ligand complexes containing 1,10-phenanthrolineand 2,2`-bipyridine. *RJPBCS* 4(1):387-397.
- Nelwan, E.J. & Wisaksana, R. 2010. Clinical manifestation of oral candidiasis in a HIV patient. *Acta Med. Indones.*, 42(1):43-44.
- Nwaka, S., Ramirez, B., Brun, R., Maes, L., Douglas, F., Ridley, R. 2009.Advancing drug innovation for neglected diseases - criteria for lead progression. *PLoS Negl Trop Dis*, 3(8):e440 doi:10.1371 /journal.pntd.0000440
- Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R.J., Larsen, R.A., Harold, W., *et al.*, 2003. Antifungal susceptibility survey of 2,000 bloodstream *Candida* isolates in the United States. *Antimicrob. Agents Chemother.*,47:3149–3154.

- Ozerdem Akpolat, N., Elçi, S., Atmaca, S., Akbayin, H.&Gül, K. 2003. The effects of magnesium, calcium and EDTA on slime production by *Staphylococcus epidermidis* strains. *Folia Microbiol* 148: 649–653.
- Parsek, M.R., Singh, P.K. 2003. Bacterial biofilms: an emerging link to disease pathogenesis. *Annu Rev Microbiol* 57(1):677–701
- Pemán, J., Cantón, E., Espinel-Ingroff, A. 2009. Antifungal drug resistance mechanisms. *Expert. Rev. Anti. Infect. Ther.*, 7(4):453-460. DOI: 10.1586/eri.09.18.
- Percival, S.L., Kite, P., Eastwood, K., Murga, R., Carr, J., Arduino, M.J., Donlan, R.M. 2005. Tetrasodium EDTA as an novel central venous catheter lock solution against biofilm. *Infect Control Hosp Epidemiol* 26:515–519.
- Perfect, J.R., Dismukes, W.E., Dromer, F., Goldman, D.L., Graybill, J.R. Harrison, T.S., *et al.* 2010. Clinical practice guidelines for the management of Cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 50:291–322
- Prasad, T., Chandra, A., Mukhopadhyay, K. Prasad, R. 2006. Unexpected link between iron and drug resistance of *Candida spp* : iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. *Antimicrob. Agent. Chemother.*, 50 (11): 3597-3606.
- Pfaller, M.A. 2012. Antifungal drug resistance: mechanisms, epidemiology and consequences for treatment. *Am. J. Med.*, 125:S3-S13.
- Pfaller, M.A. & Diekema, D.J., 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev*, 20: 133-163.
- Pfaller, M.A., Diekema, D.J., Ostrosky-Zeichner, L., Rex, J.H., Alexander, B.D., Andes, D., *et al.*, 2008. Correlation of MIC with outcome for *Candida* species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. *J Clin Microbiol*, 46:2620–2629.
- Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, and R. J. Hollis., 2000. Bloodstream infections due to *Candida* species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. *Antimicrob. Agents Chemother.*, 44:747–751.
- Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. 2006. *In vitro* susceptibilities of *Candida spp.* to caspofungin: four years of global surveillance. *J Clin Microbiol*, 44:760–763.
- Pierce, C.G., Uppuluri, P., Tummala, S., 2010. A 96 Well Microtiter Plate-based method for Monitoring Formation and Antifungal Susceptibility Testing of *Candida albicans* Biofilm. *Journal of Visualized Experiments* 44:e 2287.

- Powderly, W.G., Kobayashi, G.S., Herzig, G.P., Medoff, G. 1988. Amphotericin B-resistant yeast infection in severely immuno-compromised patients. *Am J Med*, 84:826-832.
- Raad, I., Hanna, H., Dvorak, T., Chaiban, G., Hachem, R. 2007. Optimal anti microbial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. *Antimicrob Agents Chemother*, 51(1):78-83.
- Ramage, G., Saville, S.P., Thomas, D.P. and Lopez-Ribot, J.L. 2006. Candida biofilms: an update. *Eukar Cell*, 4:633-638.
- Ramani, R., and Chaturverdi, V., 2000. Flow Cytometry antifungal Susceptibility Testing of Pathogen Yeasts other than Candida albicans and Comporation with the NCCLS Broth Microdilution Test. *Antimicrob. Agent Chemother* 44 (10) : 2752 -58.
- Rex, J. H., Cooper, C.R.Jr, Merz, W.G., Galgiani, J.N., Anaissie, E.J. 1995. Detection of amphotericin B-resistant *Candida* isolates in a broth-based system. *Antimicrob Agents Chemother*, 39 : 906-909.
- Rajendran, R., Robertson, D.P., Hodge, P.J., Lappin, D.F., Ramage, G. 2010. Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. *Mycopathologia* 170, 229–235.
- Rautemaa, R. & Ramage, G. 2011. Oral candidosis – clinical challenges of a biofilm disease. *Crit Rev Microbiol* 37: 328–336.
- Rizk, M.A.J., Falkler, W.A., and Meiller, T.F. 2004. Fungal biofilm and drug resistance. *Emerg Infect Dis* 10(1):14-19.
- da Silva Barros, M.E., de Assis Santos, D., Hamdan J.S. 2007. Evaluation of susceptibility of *Trichophyton mentagrophytes* and *Trichophyton rubrum* clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). *J. Med. Microbiol.*, 55:809-818.
- Salvesen, G.S. & Nagase, H. 2001. Inhibition of proteolytic enzymes. In: Beynon, R. and Bond, J.S. eds., *Proteolytic enzymes: a practical approach*, 2ed., Oxford University Press, Oxford.
- Sarkisova, S., Patrauchan, M.A., Berglund, D., Nivens, D.E. & Franklin, M. J. 2005. Calcium-induced virulence factors associated with the extracellular matrix of mucoid *Pseudomonas aeruginosa* biofilms. *J. Bacteriol* 187, 4327–4337.
- Sauer, K., Camper, A.K., Ehrlich, G.D., Costerton, J.W., Davies, D.G. 2002. *Pseudomonas aeruginosa* displays multiple phenotypes during development as a biofilm. *J. Bacteriol* 184(4):1140–1154.

- Sheng, C and Zhang, W. 2011. New lead structures in antifungal drug discovery. *Curr. Med. Chem.*, 2011; 18(5):733-766.
- Shibata, Y., Hiratsuka, K., Hayakawa, M.,Shiroza, T., Takiguchi,H., Nagatsuka, Y. & Abiko, Y.2003.A35-kDaco-aggregation factor is a hemin binding protein in *Porphyromonas gingivalis*. *Biochem Biophys Res Commun*, 300:351–356.
- Smoleński, P., Jaros, S.W., Pettinari, C., Lupidi, G., Quassinti, L., Bramucci, M., *et al.* 2013. New water-soluble polypyridine silver(I) derivatives of 1,3,5-triaza-7-phosphaadamantane (PTA) with significant antimicrobial and antiproliferative activities. *Dalton Trans.*, 42(18):6572-81. DOI: 10.1039/c3dt33026e.
- Sheppard D. and Lampiris H.W., 2007.Antifungal drugs.In : Katzung B.G. (Ed.), *Basic & Clinical Pharmacology*, 10th ed. The McGraw-Hill Companies Inc., New York.
- Sholikhah, E.N., Supargiyono, Jumina, Wijayanti, M. A., Tahir, I., Hadanu, R., Mustofa. 2006. *In vitro* antiplasmodial activity and cytotoxicity of new synthesized *N*-alkyl and *N*-benzyl-1,10-phenantroline derivatives. *South East Asean J Trop. Med. Public Health.*, 37(6): 1072-1077.
- Spampinato, C. and Leonardi, D. 2013. *Candida* infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. *Bio Med. Res. Inter.* Article ID 204237, 13 pages <http://dx.doi.org/10.1155/2013/204237>
- Starosta, R., Bykowska, A., Kyzioł, A., Płotek, M., Florek, M., Król, J., *et al.* 2013. Copper (I) (pseudo) halidecomplexes with neocuproine and amino methyl phosphines derived from morpholine and thiomorpholine - *in vitro* cytotoxic and antimicrobial activity and the interactions with DNA and serum albumins. *Chem Biol Drug Des*, 82(5):579-86. DOI: 10.1111/cbdd.12187.
- Stoodley, P., Sauer, K., Davies, D.G., Costerton, J.W. 2002. Biofilms as complex differentiated communities. *Annu Rev Microbiol* 56(1):187–209
- Tamura, N.K., Negri, M.F., Bonassoli, L.A., Svidzinski, T.I. 2007. Virulence factors for *Candida* spp. Recovered from intravascular catheters and hospital workers hands. *Rev Soc Bras Med Trop* 40: 91-93.
- Thelander, L., Graslund, A., Thelander, M. 1983. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanism. *Biochem Bio phys Res Commun*, 110:859-865.
- Trevor, A.J., Katzung, B.G., Master,S.B, 2010. *Pharmacology Examination & Board Review*, 9th ed. The McGraw-Hill Companies Inc., New York

- Turnidge, J., Paterson, D.L. 2007. Setting and revising antibacterial susceptibility break points. *Clin Microbiol Rev*, 20:391-408.
- Vandeputte, P., Ferrari, S. Coste, A.T. 2011. Antifungal resistance and new strategies to control fungal infections. *Int J Microbiol* 2012, Article ID 713687. doi:10.1155/2012/713687
- Vanlaere, I. & Libert, C. 2009. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. *Clin. Microbiol. Rev.*, 22(2):224-239.
- Vasudevan, R. 2014. Biofilms: microbial cities of scientific significance. *J Microbiol Exp* 1(3):00014
- Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Mars, K.A., et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis*, 46:327–360.
- Walsh, T.J., Gamaletsou, M.N., Mc Ginnis, M.R., Hayden, R.T., Kontoyiannis, D. P. 2012. Early clinical and laboratory diagnosis of invasive pulmonary, extra pulmonary, and disseminated mucormycosis (zygomycosis). *Clin Infect Dis*, 54(S1):S55–60.
- Wanger, A., Mills, K., Nelson, P.W., Rex, J.H. 1995. Comparison of E test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant *Candida* isolates. *Antimicrob Agents Chemother*, 39:2520-2522.
- Warnock, D.W. 2007. Trends in epidemiology of invasive fungal infections. *Jpn. J. Med. Mycol.*, 48:1-12.
- Wheat, L.J., Freifeld, A.G., Kleiman, M.B., Baddley, J.W., McKinsey, D.S., Loyd, J.E. 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis*, 45:807–825.
- Wijayanti, M.A., Sholikhah, E.N., Tahir, I., Handanu, R., Jumina, Supargiyono, Mustofa. 2006. Antiplasmodial activity and acute toxicity of *N*-alkyl and *N*-benzyl-1,10-phenanthroline derivatives in mouse malaria model. *J. Health Sci.*, 52(2). 794-799.
- Wijayanti, M.A., Sholikhah, E.N., Tahir, I., Handanu, R., Jumina, Cahyono, W., Supargiyono, Mustofa. 2014. Acute toxicity tests of antiplasmodial *N*-alkyl and *N*-benzyl-1,10-phenanthroline derivatives in Swiss mice. *Southeast Asian J Trop Med Public Health*, 45(3):531-536.
- Yapar, N. 2014. Epidemiology and risk factors for invasive candidiasis. *Ther Clin Risk Manag*, 4(10):95-105.
- Yapi, A.D., Mustofa, A. Valentin, O. Chavignon, J.C. Teulade, M. Mallié, J.P. Chapat, Y. Blache. 2000. New potential antimalarial agents : synthesis and

biological activities of original diaza-analogs of phenantrene. *Chem. Pharm. Bull.*, 48(12) : 1886-1889.

Zarrin, M & Mahmoudabadi, A.Z. 2009. Invasive candidiasis : a review article. *Jundishapur J Microbiol*, 2(1) :1-6.

Zhai, B. & Lin, X. 2011. Recent progress on antifungal drug development. *Curr. Pharm. Biotechnol.*, 12(8):1255-62.